Idiopathic Neuropathy Patients Are at High Risk for Metabolic Syndrome

Overview

Journal J Neurol Sci

Publisher Elsevier

Specialty Neurology

Date 2008 Jul 9

PMID 18606421

Citations 48

Authors

A Gordon Smith

Kristi Rose

J Robinson Singleton

Affiliations

Soon will be listed here.

Abstract

Background: Idiopathic neuropathy patients are at high risk of impaired glucose tolerance (IGT). Hyperglycemia, low high density lipoprotein (HDL), elevated triglycerides (TRG), hypertension and central obesity co-associate and constitute the metabolic syndrome. Patients with hyperglycemia are at high risk of having the syndrome and each of its features. Our null hypothesis was that patients with neuropathy and IGT would have a higher prevalence of other metabolic syndrome features than those without hyperglycemia. The primary objective was to determine if metabolic syndrome features other than hyperglycemia increase neuropathy risk.

Methods: The prevalence of metabolic syndrome features was determined among 219 sequential patients with idiopathic peripheral neuropathy. Subjects were classified as having IGT or normoglycemia. The prevalence of metabolic syndrome was compared to published population prevalence data. To compensate for potential referral bias, data were also compared for175 diabetic subjects without neuropathy, given the well-recognized risk of metabolic syndrome among diabetic individuals.

Results: Contrary to our hypothesis, neuropathy patients with normoglycemia and IGT shared a similarly elevated prevalence of metabolic syndrome features compared to published normal populations. Compared to diabetic subjects without neuropathy, the normoglycemic neuropathy patients had significantly higher total and LDL cholesterol, and a higher prevalence of abnormal HDL and triglycerides. The prevalence of obesity and hypertension was similar among patient groups. Normoglycemic neuropathy subjects had significantly more features of metabolic syndrome (other than hyperglycemia) than diabetics.

Conclusions: These findings demonstrate an association between neuropathy and metabolic syndrome features other than hyperglycemia. Lipid abnormalities are particularly prevalent among neuropathy subjects.

Citing Articles

Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy.

Csiha S, Hernyak M, Molnar A, Lorincz H, Katko M, Paragh G Biomedicines. 2025; 13(2).

PMID: 40002851 PMC: 11852413. DOI: 10.3390/biomedicines13020438.

Corneal nerve loss in adolescents with obesity and acanthosis nigricans.

Gad H, Dauleh H, Chirayath S, Amin R, Pasha M, Elgassim E PLoS One. 2024; 19(10):e0309761.

PMID: 39432507 PMC: 11493272. DOI: 10.1371/journal.pone.0309761.

Peripheral neuropathy in patients with gout, beyond focal nerve compression: a cross-sectional study.

Lopez-Lopez C, Corzo-Dominguez E, Montes Castillo M, Loyola-Sanchez A, Gomez-Ruiz C, Tafoya Amado A Clin Rheumatol. 2024; 43(8):2627-2636.

PMID: 38965180 DOI: 10.1007/s10067-024-07044-w.

Nerve ultrasonographic findings in diabetes mellitus are determined by anatomical location and type of diabetes.

Toth M, Szoke A, Aranyi Z Clin Neurophysiol Pract. 2023; 8:115-122.

PMID: 38152244 PMC: 10751747. DOI: 10.1016/j.cnp.2023.04.004.

Is metformin a possible treatment for diabetic neuropathy?.

Wei J, Wei Y, Huang M, Wang P, Jia S J Diabetes. 2022; 14(10):658-669.

PMID: 36117320 PMC: 9574743. DOI: 10.1111/1753-0407.13310.

References

Esenabhalu V, Schaeffer G, Graier W . Free fatty acid overload attenuates Ca2+ signaling and NO production in endothelial cells. Antioxid Redox Signal. 2003; 5(2):147-53. DOI: 10.1089/152308603764816505. View

Ukkola O, Santaniemi M . Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med (Berl). 2002; 80(11):696-702. DOI: 10.1007/s00109-002-0378-7. View

Kannel W . Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000; 13(1 Pt 2):3S-10S. DOI: 10.1016/s0895-7061(99)00252-6. View

Singleton J, Smith A, Bromberg M . Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001; 24(8):1448-53. DOI: 10.2337/diacare.24.8.1448. View

Meigs J, DAgostino Sr R, Wilson P, Cupples L, Nathan D, Singer D . Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997; 46(10):1594-600. DOI: 10.2337/diacare.46.10.1594. View

Christakis N, Fowler J . The spread of obesity in a large social network over 32 years. N Engl J Med. 2007; 357(4):370-9. DOI: 10.1056/NEJMsa066082. View

Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View

Herman R, Brower J, Stoddard D, Casano A, Targovnik J, Herman J . Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond). 2006; 31(2):226-35. DOI: 10.1038/sj.ijo.0803418. View

Tesfaye S, Chaturvedi N, Eaton S, Ward J, Manes C, Ionescu-Tirgoviste C . Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005; 352(4):341-50. DOI: 10.1056/NEJMoa032782. View

10.

Tentolouris N, Grapsas E, Stambulis E, Papageorgiou K, Katsilambros N . Impact of body mass on autonomic function in persons with type 2 diabetes. Diabetes Res Clin Pract. 1999; 46(1):29-33. DOI: 10.1016/s0168-8227(99)00069-8. View

11.

Ilanne-Parikka P, Eriksson J, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M . Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004; 27(9):2135-40. DOI: 10.2337/diacare.27.9.2135. View

12.

Singleton J, Smith A, Russell J, Feldman E . Microvascular complications of impaired glucose tolerance. Diabetes. 2003; 52(12):2867-73. DOI: 10.2337/diabetes.52.12.2867. View

13.

Smith A, Singleton J . Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci. 2006; 242(1-2):9-14. DOI: 10.1016/j.jns.2005.11.020. View

14.

Straub R, Thum M, Hollerbach C, Palitzsch K, Scholmerich J . Impact of obesity on neuropathic late complications in NIDDM. Diabetes Care. 1994; 17(11):1290-4. DOI: 10.2337/diacare.17.11.1290. View

15.

Pittenger G, Mehrabyan A, Simmons K, Amandarice , Dublin C, Barlow P . Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord. 2008; 3(2):113-21. DOI: 10.1089/met.2005.3.113. View

16.

Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M . FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab. 2002; 87(6):2913-7. DOI: 10.1210/jcem.87.6.8596. View

17.

Lewis G, Carpentier A, Adeli K, Giacca A . Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002; 23(2):201-29. DOI: 10.1210/edrv.23.2.0461. View

18.

Hughes R, Umapathi T, Gray I, Gregson N, Noori M, Pannala A . A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004; 127(Pt 8):1723-30. DOI: 10.1093/brain/awh192. View

19.

Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778. View

20.

Smith A, Russell J, Feldman E, Goldstein J, Peltier A, Smith S . Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006; 29(6):1294-9. DOI: 10.2337/dc06-0224. View